Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience
详细信息 查看全文
- 作者：Otto Metzger-Filho ; Evandro de Azambuja…
- 关键词：Breast cancer ; Disease ; free survival ; HER2+
- 刊名：Breast Cancer Research and Treatment
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：155
- 期：1
- 页码：127-132
- 全文大小：535 KB
- 参考文献：1.Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791PubMed CrossRef
2.Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119PubMed CrossRef
3.Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672PubMed CrossRef
4.Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684PubMed CrossRef
5.Slamon D et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283PubMed PubMedCentral CrossRef
6.Smith I et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36PubMed CrossRef
7.Gianni L et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12(3):236–244PubMed CrossRef
8.Tripathy D et al (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22(6):1063–1070PubMed CrossRef
9.Petrelli F, Barni S (2013) A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer 13(2):81–87PubMed CrossRef
10.Campiglio M et al (2011) Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 128(1):147–154PubMed CrossRef
11.Extra JM et al (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15(8):799–809PubMed PubMedCentral CrossRef
12.von Minckwitz G et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27(12):1999–2006CrossRef
13.Krop IE et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15(7):689–699PubMed CrossRef
14.Valagussa P, Tancini G, Bonadonna G (1986) Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58(7):1411–1417PubMed CrossRef
15.Buzdar AU et al (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47(12):2798–2802PubMed CrossRef
16.Lang I et al (2014) Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the retreatment after Herceptin Adjuvant trial. Clin Oncol (R Coll Radiol) 26(2):81–89CrossRef
17.Baselga J et al (2011) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119PubMed CrossRef
18.Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471PubMed PubMedCentral CrossRef
19.Murthy RK et al (2014) Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932–1938PubMed CrossRef
20.Vaz-Luis I et al (2013) Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer 13(4):254–263PubMed PubMedCentral CrossRef
21.Negri E et al (2014) Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study. Oncologist 19(12):1209–1215PubMed PubMedCentral CrossRef - 作者单位：Otto Metzger-Filho (1)
Evandro de Azambuja (2)
Marion Procter (3)
Magalie Krieguer (4)
Ian Smith (5)
Jose Baselga (6)
David Cameron (7)
Michael Untch (8)
Christian Jackisch (9)
Richard Bell (10)
Luca Gianni (11)
Aron Goldhirsch (12) (13)
Martine Piccart (14)
Richard D. Gelber (15)
HREA Study Team
1. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue Yawkey, Boston, 1238, USA
2. Department of Medical Oncology and Breast European Adjuvant Study Team (BrEAST) Data Centre, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium
3. Frontier Science (Scotland) Ltd, Kincraig, Kingussie, UK
4. Breast European Adjuvant Study Team (BrEAST) Data Centre, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium
5. Breast Unit, Royal Marsden Hospital, and Institute of Cancer Research, London, UK
6. Memorial Sloan-Kettering Cancer Center, New York, NY, USA
7. Edinburgh Cancer Research Centre, Western general Hospital, University of Edinburgh, Crewe Road South, Edinburgh, UK
8. Department of Gynecology and Obstetrics and Multidisciplinary Breast Cancer Center, Helios Klinikum, Berlin-Buch, Germany
9. Department of Gynecology and Obstetrics, Klinikum Off enbach, Off Enbach, Germany
10. Department of Medical Oncology, The Andrew Love Cancer Centre, Deakin University, Geelong, Australia
11. Department of Medical Oncology, San Raffaele Institute, Milan, Italy
12. European Institute of Oncology, Milan, Italy
13. Swiss Center for Breast Health, Sant’Anna Clinic, Lugano-Sorengo, Switzerland
14. Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium
15. Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, USA - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology - 出版者：Springer Netherlands
- ISSN：1573-7217
文摘
This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than <12 months (n = 84) but not statistically significant (23.7 vs. 17.8 months, p = 0.47). The median duration of first-line trastuzumab-based regimens for patients previously treated with adjuvant trastuzumab and diagnosed with distant disease recurrence was 8.8 months (n = 88). This retrospective, exploratory study suggests that TDRI did not impact on OS measured from distant recurrence. We argue that prospective collection of treatment information beyond disease progression should be included in future clinical studies.